Summary
24.58 -0.03(-0.12%)07/17/2025
Pfizer Inc. (PFE)
PFE reported last earnings on 2025-04-29 after the market. An EPS of $0.92 was observed compared to an estimated EPS of $0.666, resulting in a surprise value of $0.25. A revenue of $13,715 million was observed compared to an estimated revenue of $13,920 million, resulting in a surprise value of $-205 Million.
Pfizer Inc. (PFE)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years |
| -0.47 | -4.17 | 2.42 | 13.12 | -3.19 | -12.68 | -10.65 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan!
Fundamental Ratings
| Category | Rating |
| Main Rating | B+ |
| Recommended Rating | Neutral |
| DCF | Strong Buy |
| ROE | Neutral |
| ROA | Buy |
| Debt/Equity | Strong Sell |
| P/E | Sell |
| P/B | Buy |
Earnings
| Trading Data | ||
| Close | 24.47 | |
| Open | 24.71 | |
| High | 24.78 | |
| Low | 24.39 | |
| Volume | 27,674,550 | |
| Change | -0.12 | |
| Change % | -0.47 | |
| Avg Volume (20 Days) | 40,106,613 | |
| Volume/Avg Volume (20 Days) Ratio | 0.69 | |
| 52 Week Range | 20.72 - 29.98 | |
| Price vs 52 Week High | -18.40% | |
| Price vs 52 Week Low | 18.10% | |
| Range | 0.00 | |
| Gap Up/Down | -0.47 | |
Profitibility | ||
| Market Capitalization (Mln) | 145,199 | |
| Revenue per share | 11.0067 | |
| Net Income per share | 1.3861 | |
| Dividend Yield | 0.0862 | |
| Dividend Share | 212.00% | |
Valuations | ||
| Enterprise Value | 0.00% | |
| PE Ratio | 17.7335 | |
| PB Ratio | 0.0000 | |
| PTB Ratio | 0.0000 | |
Liquidity | ||
| Debt/Equity Ratio | 0.0000 | |
| Net Debt/EBIDTA Ratio | 0.0000 | |
| Current Ratio | 0.0000 | |
Enterprise Value and Cash Flow | ||
| EV/Sales Ratio | 0.0000 | |
| EV/EBIDTA Ratio | 0.0000 | |
| EV/Free Cash Flow Ratio | 0.0000 | |
07/18 14:46 EST - seekingalpha.com
July's 5 Dividend Growth Stocks With Yields Up To 7.96%
Dividend growth stocks can offer a stable way to passively grow one's income, creating long-term compounding wealth over the long run. Today, we are looking at a screening process that focuses on higher yields but ranks higher on dividend safety and consistency for growth. From the hundreds that...
July's 5 Dividend Growth Stocks With Yields Up To 7.96%
Dividend growth stocks can offer a stable way to passively grow one's income, creating long-term compounding wealth over the long run. Today, we are looking at a screening process that focuses on higher yields but ranks higher on dividend safety and consistency for growth. From the hundreds that...
07/17 13:11 EST - youtube.com
Trade Tracker: Josh Brown Sells Pfizer
Josh Brown, CEO of Ritholtz Wealth Management, joins CNBC's "Halftime Report" to explain why he's selling Pfizer here.
Trade Tracker: Josh Brown Sells Pfizer
Josh Brown, CEO of Ritholtz Wealth Management, joins CNBC's "Halftime Report" to explain why he's selling Pfizer here.
07/17 11:47 EST - cnbc.com
Bristol Myers Squibb, Pfizer to sell blockbuster blood thinner Eliquis at 40% discount
Bristol Myers Squibb and Pfizer said they will start selling their blockbuster blood thinner, Eliquis, directly to some patients at a more than 40% discount. The companies' new effort would bypass traditional middlemen, including pharmacy benefit managers and insurers, to cut the drug's monthly...
Bristol Myers Squibb, Pfizer to sell blockbuster blood thinner Eliquis at 40% discount
Bristol Myers Squibb and Pfizer said they will start selling their blockbuster blood thinner, Eliquis, directly to some patients at a more than 40% discount. The companies' new effort would bypass traditional middlemen, including pharmacy benefit managers and insurers, to cut the drug's monthly...
07/17 11:47 EST - 247wallst.com
3 Ultra-Safe Dividend Stocks That Yield Over 5%
Key Points These dividend stocks yield 5% or more.
3 Ultra-Safe Dividend Stocks That Yield Over 5%
Key Points These dividend stocks yield 5% or more.
07/17 11:30 EST - https://247wallst.com
Inherited $400,000? Here’s the Smartest Way to Turn It Into Monthly Passive Income
Key Points The SPHD and DIVO ETFs are ideal vehicles for volatility mitigation and reliable income. Furthermore, you can enhance your monthly income potential with single-stock ETFs. Are you ahead, or behind on retirement? SmartAsset’s free tool can match you with a financial advisor in minutes...
Inherited $400,000? Here’s the Smartest Way to Turn It Into Monthly Passive Income
Key Points The SPHD and DIVO ETFs are ideal vehicles for volatility mitigation and reliable income. Furthermore, you can enhance your monthly income potential with single-stock ETFs. Are you ahead, or behind on retirement? SmartAsset’s free tool can match you with a financial advisor in minutes...
07/17 08:45 EST - seekingalpha.com
Dividend Harvesting Portfolio Week 228: $22,800 Allocated, $2,399.27 In Projected Dividends
The Dividend Harvesting Portfolio is thriving, generating strong recurring income and capital appreciation, with forward dividend income nearing $2,400 and a yield over 8%. My disciplined weekly allocation and diversified approach—spanning 102 positions—have mitigated downside risk and steadily...
Dividend Harvesting Portfolio Week 228: $22,800 Allocated, $2,399.27 In Projected Dividends
The Dividend Harvesting Portfolio is thriving, generating strong recurring income and capital appreciation, with forward dividend income nearing $2,400 and a yield over 8%. My disciplined weekly allocation and diversified approach—spanning 102 positions—have mitigated downside risk and steadily...
07/17 08:34 EST - 247wallst.com
I Sold Pfizer at a 13% Loss – Here's Why I'm Choosing Stability Over Risk
A Reddit poster took a big loss on Pfizer. They needed to dump some shares because they occupied a huge chunk of their portfolio.
I Sold Pfizer at a 13% Loss – Here's Why I'm Choosing Stability Over Risk
A Reddit poster took a big loss on Pfizer. They needed to dump some shares because they occupied a huge chunk of their portfolio.
07/17 06:59 EST - businesswire.com
Bristol Myers Squibb and Pfizer Announce Direct-to-Patient Eliquis® (apixaban) Option
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb and Pfizer Announce Direct-to-Patient Eliquis® (apixaban) Option.
Bristol Myers Squibb and Pfizer Announce Direct-to-Patient Eliquis® (apixaban) Option
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb and Pfizer Announce Direct-to-Patient Eliquis® (apixaban) Option.
07/17 06:30 EST - wsj.com
Bristol-Myers Squibb and Pfizer plan to sell the widely used blood thinner Eliquis directly to patients at a discounted cash price
The joint venture is launching a direct-to-consumer service of Eliquis after discussions with the Trump administration.
Bristol-Myers Squibb and Pfizer plan to sell the widely used blood thinner Eliquis directly to patients at a discounted cash price
The joint venture is launching a direct-to-consumer service of Eliquis after discussions with the Trump administration.
07/16 04:12 EST - fool.com
This Once-Dominant Healthcare Stock Down 50% Is Finally Ready for a Comeback
A few years ago, Pfizer (PFE -2.86%) was on top of the world when it came to earnings and stock price performance. The pharma giant recorded a record of $100 billion in sales back in 2022, and saw its shares rise 60% over nearly two years through a peak in late 2021.
This Once-Dominant Healthcare Stock Down 50% Is Finally Ready for a Comeback
A few years ago, Pfizer (PFE -2.86%) was on top of the world when it came to earnings and stock price performance. The pharma giant recorded a record of $100 billion in sales back in 2022, and saw its shares rise 60% over nearly two years through a peak in late 2021.
07/15 09:55 EST - zacks.com
How Will Pfizer's Oncology Drugs Perform in Q2 Earnings?
PFE's oncology unit is in focus ahead of Q2 results, with key drugs facing both rising demand and market pressure.
How Will Pfizer's Oncology Drugs Perform in Q2 Earnings?
PFE's oncology unit is in focus ahead of Q2 results, with key drugs facing both rising demand and market pressure.
07/15 04:21 EST - proactiveinvestors.co.uk
Oxford BioDynamics shares jump 66% after Pfizer validates blood-based cancer biomarker technology
Oxford BioDynamics PLC (AIM:OBD) shares jumped 66% after Pfizer published data confirming the effectiveness of the company's EpiSwitch blood-based biomarkers in monitoring tumour status and treatment response in bladder cancer patients. The findings, from the JAVELIN Bladder 100 Trial involving 496...
Oxford BioDynamics shares jump 66% after Pfizer validates blood-based cancer biomarker technology
Oxford BioDynamics PLC (AIM:OBD) shares jumped 66% after Pfizer published data confirming the effectiveness of the company's EpiSwitch blood-based biomarkers in monitoring tumour status and treatment response in bladder cancer patients. The findings, from the JAVELIN Bladder 100 Trial involving 496...
07/14 18:45 EST - zacks.com
Pfizer (PFE) Stock Sinks As Market Gains: Here's Why
Pfizer (PFE) concluded the recent trading session at $25.35, signifying a -1.17% move from its prior day's close.
Pfizer (PFE) Stock Sinks As Market Gains: Here's Why
Pfizer (PFE) concluded the recent trading session at $25.35, signifying a -1.17% move from its prior day's close.
07/14 10:00 EST - zacks.com
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
07/11 13:29 EST - 247wallst.com
“Nobody Ever Went Broke Taking a Profit” – Grab The Highest-Yielding S&P 500 Stocks Right Now
A Wall Street maxim states, “Twenty percent of investors who want to make money are in stocks, while the other 80 percent who want to keep their money are in bonds.
“Nobody Ever Went Broke Taking a Profit” – Grab The Highest-Yielding S&P 500 Stocks Right Now
A Wall Street maxim states, “Twenty percent of investors who want to make money are in stocks, while the other 80 percent who want to keep their money are in bonds.
07/11 13:11 EST - zacks.com
Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report?
Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report?
Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
07/10 10:30 EST - https://247wallst.com
How to Build a Low-Cost Portfolio for $5,000 Without Taking Risks
Key Points Focus on low-priced, low-beta stocks to populate your $5,000 portfolio. Add in a few low-cost, risk-reduced ETFs for enhanced diversification. Are you ahead, or behind on retirement? SmartAsset’s free tool can match you with a financial advisor in minutes to help you answer that today....
How to Build a Low-Cost Portfolio for $5,000 Without Taking Risks
Key Points Focus on low-priced, low-beta stocks to populate your $5,000 portfolio. Add in a few low-cost, risk-reduced ETFs for enhanced diversification. Are you ahead, or behind on retirement? SmartAsset’s free tool can match you with a financial advisor in minutes to help you answer that today....
07/10 08:17 EST - seekingalpha.com
3 To Watch Of 23 'Safer' July Dividends From 46 Fortune World's Most Admired Companies
I analyze the 50 Fortune World's Most Admired Companies, focusing on dividend-paying stocks and their yield-based investment potential. Three companies—Pfizer, BMW, and Singapore Airlines—currently meet my 'IDEAL' dividend criteria, with dividends from $1K invested exceeding their single share...
3 To Watch Of 23 'Safer' July Dividends From 46 Fortune World's Most Admired Companies
I analyze the 50 Fortune World's Most Admired Companies, focusing on dividend-paying stocks and their yield-based investment potential. Three companies—Pfizer, BMW, and Singapore Airlines—currently meet my 'IDEAL' dividend criteria, with dividends from $1K invested exceeding their single share...